SCHEMBL15134657

SCHEMBL15134657

CCCCC(O)(C#Cc1cccc(C(=O)OCC)n1)CCCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.54
MAPT P10636 2/20 0.45
GAA P10253 1/20 0.38
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
GRM5 P41594 3/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 3/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15134655 0.80 KCNH2 (0.31)
SCHEMBL2768062 0.77 CYP1A2 (0.66) CYP1A2MAPTGAAALDH1A1POLB
SCHEMBL13162467 0.76 CYP1A2 (0.64) CYP1A2MAPTGAAALDH1A1POLB
SCHEMBL22070957 0.74 CYP1A2 (0.57) CYP1A2MAPTGAACTSLCTSB
SCHEMBL2962800 0.74 CYP1A2 (0.70) CYP1A2MAPTGAAALDH1A1POLB
SCHEMBL1478915 0.72 CYP1A2 (1.00) CYP1A2MAPTGAAALDH1A1POLB
SCHEMBL31186044 0.71 CYP1A2 (0.47) CYP1A2MAPTGAAMAPK1GRM5
SCHEMBL22701452 0.69 CYP1A2 (0.83) CYP1A2MAPTGAAALDH1A1POLB
SCHEMBL109583 0.68 CYP1A2 (0.82) CYP1A2MAPTGAAALDH1A1POLB
SCHEMBL3885590 0.67 CYP1A2 (0.68) CYP1A2MAPTALDH1A1MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447078-B2 Substituted heterocyclic compounds for disease treatment ACUCELA INC. (US) 2016-09-20 US disclosed
US-9447078-B2 Substituted heterocyclic compounds for disease treatment ACUCELA INC. (US) 2016-09-20 US disclosed
US-20130225619-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. (US) 2013-08-29 US disclosed
US-20130225619-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. (US) 2013-08-29 US disclosed
WO-2013109991-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. (US) 2013-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225619-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT CLN6, ALDH1A2, PDE6D CYP1A2 3298/4885MAPT 59/4885GAA 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.